Repeated COVID vaccines enhance mucosal immunity against the virus

People who received multiple doses of mRNA vaccines showed more neutralizing antibodies in nasal secretions

Ghent, October 24, 2024 – During the COVID pandemic, many of us have received multiple mRNA vaccines. New work by researchers at the VIB-UGent Center for Inflammation Research, Ghent University, and University Hospital Ghent, among others, has found that such repeated vaccinations lead to the presence of mucosal antibodies, for example, inside the nose. Their work appears in Science Translational Medicine.

Protective booster shots

Part of the global response strategy against the COVID pandemic involves the administration of booster shots, or ‘vaccine updates’ to ensure protection against new variants of the SARS-CoV-2 virus.

The researchers set out to investigate the effects of multiple mRNA vaccines on mucosal immunity, referring to mucous membranes such as the ones on the inside of our noses. Specifically, the research involved a cohort of 183 participants who were sampled at multiple time points after primary and booster vaccinations.

PhD student Jozefien Declercq (VIB-UGent) explains: ​ “We found that individuals who received multiple doses of mRNA vaccines exhibited a marked increase in neutralizing antibodies in nasal secretions, which are essential for blocking viral entry. Not only that, but the immune responses generated by mRNA vaccines may persist longer than previously thought, which provides hope for sustained protection against emerging variants of the virus.”

From the blood to the nose

How do the antibodies produced in response to the vaccine get to the nose, though?

Prof. Dr. Stijn Vanhee (VIB-UGent), co-senior author of the study, explains. “Using a mouse model, we discovered that most mucosal neutralizing antibodies were of systemic origin, with antibodies circulating in the blood migrating to the respiratory mucosa in the nose, suggesting that repeated vaccination stimulates systemic antibody production that can reach mucosal membranes.”

The findings suggest that repeated vaccinations not only bolster systemic immunity but also enhance mucosal antibody responses, providing a more robust defense against the virus.

Prof. Dr. Linos Vandekerckhove (Ghent University), co-senior author of the study, emphasizes the critical role of mucosal immunity in the fight against COVID-19. "Our study provides compelling evidence that repeated mRNA vaccinations can improve mucosal antibody responses, or stimulate pre-existing infection induced mucosal responses, which are vital for preventing infection at the entry points of the virus. This could have profound implications for public health strategies moving forward, especially as we face new variants of concern.”
Jozefien Declercq, Stijn Vanhee, and Linos Vandekerckhove.

Publication

Repeated COVID-19 mRNA-based vaccination contributes to SARS-CoV-2 neutralizing antibody responses in the mucosa. Declercq et al. Science Translational Medicine, 2024.

Funding

This study was funded by Research Foundation Flanders (FWO), the European Research Council (ERC), Ghent University, and VIB’s Grand Challenges program.


Gunnar De Winter

Gunnar De Winter

Science Communications Expert, VIB

Share

Latest stories

Website preview
MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-based Biotherapeutic Product Pipeline
Ghent, Belgium – September 04, 2025 – MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round.
press.vib.be
Website preview
Spica Therapeutics Secures €1 Million VLAIO Grant to Advance Groundbreaking Macrophage-Targeted Cancer Therapy
Antwerp, Belgium - 27 August, 2025 - Spica Therapeutics, a pioneering biotech company focused on harnessing macrophage biology to develop transformative therapies across multiple disease areas, announced today that it has been awarded a €1.0 million grant from Flanders Innovation & Entrepreneurship (VLAIO).
press.vib.be
Website preview
Scientists map dendritic cell reactions to vaccines 
Ghent, 26 August 2025 – Belgian scientists have uncovered new details about how the immune system responds to vaccines. Dendritic cells, which are key immune messengers that help kick-start the body’s defenses, show specific responses to lipid nanoparticles. These findings, published in Cell Reports, could lead to safer and more effective vaccines.  
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be